TD2 Oncology delivers fully integrated preclinical, regulatory, and clinical services for cancer drug development. Partnership brings together deep clinical expertise and novel radiopharmaceutical ...

"Among the benefits of radiopharmaceuticals is the ability to precisely target cancer cells while minimizing damage to healthy tissues. Our approach can help shrink the cancer, slow its growth, and/or ...

The global CRO market is projected to hit almost $63 billion by the end of the decade, growing an average of 7.39% annually from 2025 to 2030, according to a new report from Irish-based market ...

Completion of patient dosing in the registrational Phase 2 clinical trial for 64 Cu-PSMA-I&T - a PET radiopharmaceutical targeting ...

In a major leap for cancer care at the University of Missouri, the School of Medicine and MU Health Care have launched their first clinical trial using a leading-edge therapy manufactured on campus at ...

Reston, VA (August 11, 2025)--The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is proud to announce the launch of the Global Radiopharmaceutical Trial Finder a revolutionary, AI-powered ...

The first three patients in the world have been treated in a Phase 1 clinical trial of RYZ401. RYZ401 is a novel radiopharmaceutical that specifically targets somatostatin receptors on neuroendocrine ...

The MarketWatch News Department was not involved in the creation of this content. -- Aiming to establish af-001 as a new therapeutic option for radioactive iodine (RAI)-naïve patients with ...

Three world-leading nuclear medicine organizations--the SNMMI Clinical Trials Network (SNMMI-CTN), the Australasian Radiopharmaceutical Trials Network (ARTnet), and the European Association of Nuclear ...